At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 7 enrolled
Drug / intervention
Optune NovoTTF-200A Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
HUMC 1612: A Phase I Trial of the Optune NovoTTF-200A System With Concomitant Temozolomide and Bevacizumab in Pediatric Patients With High-grade Glioma
In Brief
A Phase 1 clinical trial evaluating Optune NovoTTF-200A System for High Grade Glioma and Ependymoma. Completed, enrolled 7 participants across 2 sites.
Detailed Summary
The purpose of this study is to determine if the Optune NovoTTF-200A device can be safely used in combination with chemotherapy in pediatric patients with recurrent high-grade glioma and ependemoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHigh Grade Glioma, Ependymoma
CountriesUnited States
CollaboratorsNovoCure Ltd.
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
Enrollment StartApr 2017
First PostedApr 2017
Primary CompletionJul 2024
Study CompletionApr 2025
TodayJul 2026
First PostedApr 25, 2017
Enrollment StartApr 6, 2017
Primary CompletionJul 8, 2024
Study CompletionApr 5, 2025
TodayJul 2, 2026
Enrollment to primary: 7.3 yearsPosted 9.2 years ago
Interventions
Optune NovoTTF-200A Systemdevice
Optune NovoTTF-200A System receive treatment with 200kHz for a minimum of 18 hours per day in 28 day cycles combined with Temozolomide and Bevacizumab.